<DOC>
	<DOC>NCT02638337</DOC>
	<brief_summary>The objective of this study is to evaluate the efficacy and safety of ospemifene 60 mg once daily (QD) compared with placebo in treatment of vulvo-vaginal atrophy (VVA) due to menopause in women with moderate to severe vaginal dryness as the most bothersome symptom (MBS) of VVA.</brief_summary>
	<brief_title>Study to Evaluate Ospemifene in Patients With Moderate to Severe Vaginal Dryness Due to Menopause</brief_title>
	<detailed_description />
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>Subject is postmenopausal. Subject has moderate to severe vaginal dryness as the selfreported MBS of VVA. Subject has clinically significant abnormal findings in the physical examination. Subject has a body mass index (BMI) equal to or greater than 38 kg/m^2 Subject has uncontrolled hypertension. Subject has clinically significant abnormal findings in the gynecological examination other than signs of vaginal atrophy. Subject has uterine/vaginal bleeding of unknown origin. Subject has a vaginal infection requiring medication (may be treated and be eligible for study).</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Vulvo-vaginal Atrophy</keyword>
	<keyword>menopause</keyword>
</DOC>